Teva Launches New “Pivot to Growth” Strategy
Teva Pharmaceutical Industries Ltd. today announced a new strategic framework with four main pillars to position the Company for a new era of growth.
Uncategorized
NanoVibronix Issues Letter to Shareholders – May 18, 2023
NanoVibronix, Inc. today issued a letter to shareholders from its Chief Executive Officer, Brian Murphy, providing a review of the first quarter 2023 and recent business developments.
NanoVibronix Issues Letter to Shareholders – May 18, 2023 Read More »
Protalix BioTherapeutics Announces $20 Million Milestone Payment from Chiesi Global Rare Diseases
Protalix BioTherapeutics, Inc. today announced that it is eligible to receive a $20 million milestone payment from its commercial partner, Chiesi Global Rare Diseases, a business unit of the Chiesi Group.
BD Launches World’s First Spectral Cell Sorter with High-Speed Cell Imaging
BD (Becton, Dickinson and Company) announced the worldwide commercial launch of a new-to-world cell sorting instrument featuring two breakthrough technologies that enable researchers to uncover more detailed information about cells that was previously invisible in traditional flow cytometry experiments.
BD Launches World’s First Spectral Cell Sorter with High-Speed Cell Imaging Read More »
Affinia Therapeutics Presents New Preclinical Data on Novel AAV Capsids for Skeletal Muscle, Cardiac Muscle, and CNS at the American Society of Gene & Cell Therapy 26TH Annual Meeting
Affinia Therapeutics today announced the presentation of new preclinical data on novel AAV capsids for skeletal muscle, cardiac muscle, and central nervous system (CNS).
Oncomatryx acquires Tube Pharmaceuticals GmbH to consolidate its pioneering pipeline of ADCs targeting the tumor microenvironment
Oncomatryx has acquired Tube Pharmaceuticals GmbH, the developer of the Cytolysin toxic payload.
EXOSOME DIAGNOSTICS RELEASES INTERIM RESULTS FROM CLINICAL STUDY OF PROSTATE CANCER RISK TEST
Bio-Techne Corporation (NASDAQ: TECH) today announced that Exosome Diagnostics, a Bio-Techne brand, has reported interim results from a previously published prospective, randomized study more than 1,000 patients aimed at evaluating the clinical utility of the ExoDx™ Prostate Test over a 5-year follow-up period.
Kymera Therapeutics Presents Clinical Data from the Phase 1 Trial of IRAK4 Degrader, KT-474 (SAR444656), at the European Academy of Dermatology and Venereology Symposium
Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation (TPD) to deliver novel small molecule protein degrader medicines, today presented positive Phase 1 clinical data from its lead program, KT-474 (SAR444656), a potent, highly selective, orally bioavailable IRAK4 degrader.
Orchard Therapeutics Presents Data from Research Programs at ASGCT Demonstrating the Ability of HSC Gene Therapy to Address Larger Indications
Orchard Therapeutics today presented new data from the company’s hematopoietic stem cell (HSC) gene therapy research pipeline targeting larger indications at the ongoing 26th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) in Los Angeles.
MedAvail to Report First Quarter 2023 Financial Results on May 18
MedAvail Holdings, Inc. today announced that the Company will announce financial results for the first quarter ended March 31, 2023, on Thursday, May 18th, after the close of the financial markets.
MedAvail to Report First Quarter 2023 Financial Results on May 18 Read More »